User profiles for J. M. Schvartzman

Juan Manuel Schvartzman

Memorial Sloan Kettering Cancer Center
Verified email at mskcc.org
Cited by 1649

Mitotic chromosomal instability and cancer: mouse modelling of the human disease

JM Schvartzman, R Sotillo, R Benezra - Nature Reviews Cancer, 2010 - nature.com
The stepwise progression from an early dysplastic lesion to full-blown metastatic malignancy
is associated with increases in genomic instability. Mitotic chromosomal instability — the …

Metabolic regulation of chromatin modifications and gene expression

JM Schvartzman, CB Thompson, LWS Finley - Journal of Cell Biology, 2018 - rupress.org
Dynamic regulation of gene expression in response to changing local conditions is critical
for the survival of all organisms. In metazoans, coherent regulation of gene expression …

Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal

R Sotillo, JM Schvartzman, ND Socci, R Benezra - Nature, 2010 - nature.com
Inhibition of an initiating oncogene often leads to extensive tumour cell death, a phenomenon
known as oncogene addiction 1 . This has led to the search for compounds that …

[PDF][PDF] Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition

JM Schvartzman, PHG Duijf, R Sotillo, C Coker… - Cancer cell, 2011 - cell.com
Multiple mechanisms have been proposed to explain how Rb and p53 tumor suppressor
loss lead to chromosome instability (CIN). It was recently shown that Rb pathway inhibition …

Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo

…, R Sotillo, JM Schvartzman… - Proceedings of the …, 2008 - National Acad Sciences
Hec1 (Highly Expressed in Cancer 1) is one of four proteins of the outer kinetochore Ndc80
complex involved in the dynamic interface between centromeres and spindle microtubules. …

Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition

JJ Harding, MA Lowery, AH Shih, JM Schvartzman… - Cancer discovery, 2018 - AACR
IDH-mutant cancers can develop resistance to isoform-selective IDH inhibition by “isoform
switching” from mutant IDH1 to mutant IDH2 or vice versa, thereby restoring 2HG production …

Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination

JM Schvartzman, G Forsyth, H Walch, W Chatila… - Molecular Cell, 2023 - cell.com
Oncogenic mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) produce 2-hydroxyglutarate
(2HG), which inhibits dioxygenases that modulate chromatin dynamics. The effects of …

2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation

JM Schvartzman, VP Reuter… - Proceedings of the …, 2019 - National Acad Sciences
Oncogenic IDH1/2 mutations produce 2-hydroxyglutarate (2HG), resulting in competitive
inhibition of DNA and protein demethylation. IDH-mutant cancer cells show an inability to …

D-2HG comes out of its shell: Metabolic effects on the immune environment

JM Schvartzman, AM Intlekofer - Molecular Cell, 2022 - cell.com
… Juan Manuel Schvartzman1,* and Andrew M. Intlekofer2,* 1Division of Hematology &
Oncology, Department of Medicine, Columbia University Medical Center, New York, NY …

Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma

…, LM Pak, T Boerner, G Askan, JM Schvartzman… - Human pathology, 2019 - Elsevier
Intrahepatic cholangiocarcinoma has known histological heterogeneity. Mutations in IDH1 (mIDH1)
define a molecular subclass of intrahepatic cholangiocarcinoma and IDH-targeted …